Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer Clinical Trial

Official title:

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05777603
• Other study ID #: 10001516
• Secondary ID: 001516-C
• Status: Recruiting
• Phase: Phase 1
• Start date: April 18, 2024
• Est. completion date: June 1, 2027

Study information

• Verified date: June 7, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Shannon G Swift, R.N.
• Phone: (240) 858-3157
• Email: shannon.swift[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate their lungs. These bacterial changes may aid tumor growth. Researchers want to find out if treating the bacteria, too, can help cancer treatment work better.

Objective:

To test 2 inhaled antibiotics (aztreonam and vancomycin), combined with a standard cancer treatment, in people with NSCLC.

Eligibility:

People aged 18 years and older with NSCLC that has returned or progressed after treatment and cannot be treated with surgery.

Design:

Participants will be screened. They will have a physical exam with blood tests. They may blow into a machine to test how well their lungs work. They will have imaging scans. They may need to have a small piece of tissue cut from their tumor (biopsy).

Participants will be treated in six 21-day cycles. They will visit the clinic to receive a drug for cancer treatment on the first day of each cycle. This drug will be administered through a tube attached to a needle inserted into a vein in the arm.

The 2 antibiotic drugs will be in the form of a fine mist that can be inhaled. Participants use a device to take these drugs at home. They will inhale aztreonam up to 3 times a day and vancomycin 1 or 2 times a day. They will take these drugs during only 3 of the treatment cycles.

Biopsies and other tests will be repeated halfway through and after the study treatment.

Follow-up visits will continue for 1 year after study treatment.

Description:

Background:

• Dysbiosis of the lung microbiome is commonly seen in patients with advanced non-small cell lung cancer (NSCLC). It is associated with increased bacterial burden and decreased bacterial diversity in tumors

• Preclinical studies using genetically engineered mouse (GEM) models show that dysbiosis of the lung microbiome promotes tumor growth in NSCLC

Objective:

• To assess the safety of combined aerosolized antibiotics (aztreonam and vancomycin) with pembrolizumab IV, in participants with advanced NSCLC

Eligibility:

• Histological confirmation of NSCLC that is not amenable to surgery

• Received at least one previous line of standard frontline therapy that must include a PD-1/PD-L1-targeting ICI

• PD-L1Tumor Proportion Score (TPS) >=1% detected at any time since diagnosis.

• Measurable and progressive disease

• Age >=18 years

• ECOG performance status <=2

• Participants must have adequate organ and bone marrow function

Design:

• This is a phase I, open-label, single-arm study evaluating the safety and feasibility of combined aerosolized antibiotics (aztreonam and vancomycin) and pembrolizumab in advanced NSCLC

• Participants will be given six cycles of treatments; each cycle is three weeks (21 days)

• Participants receive pembrolizumab 200mg IV on Day 1 of each cycle

• During cycles 1, 3 and 5, participants will self-administer aerosolized aztreonam 3 times a day and vancomycin twice a day from Day 2 through Day 21

• There are two dose levels of aerosolized antibiotics: participants start with Dose Level 1 (aztreonam 75mg three times a day and vancomycin 250mg twice a day)

• If participants cannot tolerate Dose Level 1, treatment will be de-escalated to Dose Level

• 1 (aztreonam 75mg once a day and vancomycin 250mg once a day)

• Participants will be enrolled based on 3+3 scheme to test the primary endpoints of safety and feasibility

• Up to 18 evaluable participants will be enrolled

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 1, 2027
• Est. primary completion date: June 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

• INCLUSION CRITERIA:

1. Histologically or cytologically non-small cell lung cancer confirmed by outside pathology report or via the Laboratory of Pathology, NCI.

2. Have measurable disease, per RECIST 1.1, that is not amenable to surgery.

3. PD-L1 Tumor Proportion Score (TPS) >=1% detected at any time since diagnosis, based on a pathology report from an outside hospital or Laboratory of Pathology, NCI. PD- L1 expression testing must be conducted using one of the FDA approved diagnostic devices listed here: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list- cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools.

4. Received at least one previous line of standard frontline therapy that must include a PD-1/PD-L1-targeting ICI.

5. Age >=18 years.

6. ECOG performance status <=2.

Must have adequate organ and marrow function as defined below:

Leukocytes >=3,000/mcL

absolute neutrophil count >=1,500/mcL

platelets >=100,000/mcL

total bilirubin<TAB>within normal institutional limits

AST/ALT <=2.5 X institutional upper limit of normal

creatinine clearance<TAB>>=60 mL/min/1.73 m^2 (calculated based on CKD-EPI formula or directly measured) for participants with creatinine levels above institutional normal.

7. Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.

8. Participants with new or progressive brain metastases (active brain metastases) are eligible if immediate CNS specifictreatment is not required per standard of care and is unlikely to be required during the first cycle of therapy.

9. Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within the 6 months before study treatment initiation are eligible for this trial.

10. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

11. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

12. Women of child-bearing potential (WOCBP) must agree to use effective contraception (e.g., hormonal intrauterine device [IUD], tubal ligation, partner has had prior vasectomy) beginning at study entry until 4 months after the completion of therapy. Note: abstinence, defined as no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the participant is also acceptable.

13. Breastfeeding participants must be willing to discontinue breastfeeding for the duration of study treatment.

14. Ability of participant to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

1. Participants who are receiving any other investigational agents.

2. Participants with ongoing Epstein-Barr virus or cytomegalovirus infection

3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, aztreonam, vancomycin and albuterol.

4. Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed in females of childbearing potential at screening).

5. Pulmonary function FEV1 (Forced Expiratory Volume in the first second) <25% will be excluded based on the requirement of receiving aerosolized aztreonam.

6. Participants with targetable EGFR, ALK, ROS1, BRAF V600E, NTRK1/2/3, METex14 skipping, RET, and HER2 genomic tumor aberrations. Genomic testing must be based on a pathology report from an outside hospital or Laboratory of Pathology, NCI and must be conducted using TSO500 or one of the FDA approved diagnostic devices listed here: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or- approved-companion-diagnostic-devices-in-vitro-and-imaging-tools.

7. Participants with KrasG12C mutation not previously treated with sotorasib or other approved KrasG12C small molecule inhibitor.

8. History of severe immune-related adverse events (irAEs), defined as any grade neurological or cardiac irAEs, any grade 3 or 4 irAE (except fully controlled endocrine irAEs with appropriate hormone supplementation), and any grade pneumonitis.

9. Uncontrolled intercurrent illness that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Advanced Non Small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• aerosolized aztreonam
antibiotic with gram-negative bacteria coverage
• aerosolized vancomycin
antibiotic with gram-positive bacteria coverage
• pembrolizumab
standard of care therapy/monoclonal antibody for patients with advanced NSCLC

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicities (DLTs) - type and grade	Safety will be evaluated by reported grades of toxicities, including DLTs at each dose levels.	Start of therapy through 1 year after last study drug dose
Secondary	Dose limiting toxicities (DLTs) - type and grade	Recommended phase 2 dose will be determined by reported grades of toxicities, including DLTs at each dose levels.	Start of therapy through 1 year after last study drug dose.
Secondary	Fraction of participants who received adequate doses of all agents at each dose level	Feasibility will be reported as the fraction of participants who receive adequate doses of all drug agents without DLT at each dose level.	Between start of therapy through 1 year after last study drug dose.

External Links

•   NIH Clinical Center Detailed Web Page